Sleep Well Observation Study

NCT ID: NCT05748574

Last Updated: 2024-08-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-14
• Study Completion Date: 2023-08-03

Brief Summary

Insomnia is characterized by the recurring difficulty to fall or remain asleep despite motivation and means to do so. People with insomnia also experience excessive daytime sleepiness and other cognitive impairments while they are awake. Facing the situation mentioned and realizing that especially early preventive measures are needed to fight the increasing costs for treatment of sleep related diseases, effective nutrients might be a good and safe option to improve sleep quality.This single-arm, open-label, prospective, observational exploratory pilot study aims at collecting first data on efficacy and safety of "Sleep Well".

Detailed Description

This single-center study is a one-armed, open-label, prospective, observational exploratory pilot study and has a duration of 17 days per participant. A total of 50 healthy participants (n=25 female, n=25 male) aged 18-50 years inclusive reported sleep problems at a preliminary stage to the criteria of the German "S3 guideline non-restorative sleep/sleep disorders - insomnia in adults" for the definition of non-organic insomnia according to ICD-10 (F 51.0) are included into the study.

The total study population of N=50 will include two groups: A subgroup of n=40 will not undergo polysomnographic assessment (nonPSG), a group of n=10 will undergo polysomnographic assessment (PSG), in addition to all other assessments. The nonPSG group has a total of 3 study centre visits (V1, V2, V3) and and the PSG group has two further visits prior to V2 and V3 resulting in five study centre visits (V1, V2-1, V2, V3-1, V3). Except for the PSG, all other assessments are identical in the two groups.

All included individuals will take one Sleep Well sachet daily over an intake period of 14 days with an acute dosage at two visits.

Conditions

Sleep Disturbance

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sleep Well Sachet "Treatment"

Sachet of Sleep Well direct granulate (2.0 g)

1 sachet contains: 190 mg standardized dry extract of Melissa officinalis leaf , 75 mg dried pressed juice of fresh Lactuca sativa herb, 0.41 g Magnesiumdicitrate, 0.12 g L-Tryptophan, excipients and natural flavors.

Group Type: EXPERIMENTAL

Sleep Well Sachet

Intervention Type: DIETARY_SUPPLEMENT

Individuals will take 1 Sleep Well sachet daily over 2 weeks Exception: Two sachets are taken on days 4 and 17 upon acute assessment

Interventions

Sleep Well Sachet

Individuals will take 1 Sleep Well sachet daily over 2 weeks Exception: Two sachets are taken on days 4 and 17 upon acute assessment

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• • Voluntary, written, informed consent to participate in the study.

• Male or female aged between 18-50 years (inclusive).
• Self reported sleep problems precursing the criteria of the German "S3 guideline non-restorative sleep/sleep disorders - insomnia in adults".
• Habitual bedtime between 9 pm and midnight.
• Agreement to avoid foods such as pitted fruit, bananas and chocolate 24 hours before saliva sample collection.
• Willing to download wearable app.
• Easy access to internet for daily e-diary.
• Cooling capacities available for storage of saliva samples

Exclusion Criteria

• • Body mass index (BMI) <18.0 or >30.0 kg/m2.

• Women who are currently pregnant or breastfeeding.
• Any known history of a disorder affecting sleep quality, such as narcolepsy, obstructive sleep apnea (OSA), restless leg syndrome (RLS), periodic limb movement syndrome (PLMS) or any organic caused sleep disorders e.g. benign prostatic hyperplasia (BPH), renal insufficiency, hepatopathy, urinary tract infections, irritated bladder, or any psychiatric disorder, e.g. depression, anxiety.
• Have a significant acute or chronic coexisting illness or any condition which contraindicates entry to the study in the opinion of the Investigator (e.g. migraines, active infections).
• Previous (last 4 weeks prior to screening) or current intake of drugs that could influence sleep patterns including hormone therapy, health products and oriental herbs.
• Binge drinking (males >140 g/week, females >70 g/week), heavy smoking (>10 cigarettes/day), high caffeine intake (>10 glasses/day).
• Self-declared illicit drug use (including cannabis and cocaine) for 3 months prior to screening and during the intervention period.
• Have a high blood pressure (systolic over 159 mmHg or diastolic over 99 mmHg).
• Have learning and/or behavioural difficulties such as dyslexia or attention deficit hyperactivity disorder (ADHD).
• Have a visual impairment that cannot be corrected with glasses or contact lenses (including colour-blindness).
• History or planned travel to a different time zone within 1 month of the first visit or/and during the study participation.
• Not fluent in German.
• Have relevant food allergies/intolerances/sensitivities to any substance in the study product.
• Have oral disease.
• Participation in another study with any investigational product within 30 days of screening and during the intervention period.
• Investigator believes that the participant may be uncooperative and/or noncompliant and should therefore not participate in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Daacro GmbH & Co. KG

UNKNOWN

Sponsor Role: collaborator

Biochemical Laboratory of the Department of Psychobiology, University of Trier

UNKNOWN

Sponsor Role: collaborator

SYNLAB GmbH

UNKNOWN

Sponsor Role: collaborator

A. Vogel AG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Juliane Hellhammer, Dr

Role: PRINCIPAL_INVESTIGATOR

daacro GmbH & Co. KG, Science Park Trier, Max-Planck-Str. 22, 54296 Trier/Germany

Locations

daacro GmbH & Co. KG

Trier, Rhineland-Palatinate, Germany

Countries

Germany

Other Identifiers

5'000'749-1

Identifier Type: -

Identifier Source: org_study_id